Latest Conference Content

A lively debate on the pros and cons of using hormone therapy in women to prevent cardiovascular events had attendees engaged throughout.

Varsha Tanguturi, MD, cardiologist and DETECT AS investigator, presented new data on how the findings she and her colleagues saw indicate almost universal increases in rates of aortic valve replacement in patients with severe aortic stenosis (AS), across both provider and patient groups.

Khush Kharidia, MD, a third-year internal medicine resident at UT Southwestern, presented the oral abstract, “Evaluating the Quality, Accuracy and Health Impact of Cholesterol-Related Content on TikTok: A Social Media Analysis,” at ASPC 2025 Congress on CVD Prevention.

Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.

Language models and wearable devices are just 2 means of improving the practice of preventive cardiology.

Alexandra M. Trevino, MD, of Northwestern Medicine presented the oral abstract, "Trends in New-Onset Hypertensive Disorders of Pregnancy Among US Adults by Place of Birth and Hispanic Ethnic Origin Group," on day 1 of the ASPC Congress on CVD Prevention.

Experts provided insights into how past cohort studies have helped to shape preventive medicine for more than 50 years.

Noting the profound impact of living with a chronic condition that constantly reminds patients of their "patient" status, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the importance of therapies that can offer a sense of normalcy.

David J. Maron, MD, FASPC, president-elect of the American Society for Preventive Cardiology (ASPC), previews hot topics of interest at this year's congress and how lessons he has learned from current ASPC president Michael Shapiro, DO, FASPC, will shape his presidency set to commence next year.

At the 2025 Society for Pediatric Dermatology conference, Karen Vo, DO, presented research analyzing popular TikTok videos about epidermolysis bullosa, highlighting the platform’s power in raising awareness through emotional storytelling, and used her findings to advocate for early school-based mental health support and stronger, more inclusive antibullying policies for children with chronic skin conditions.

At the Society for Pediatric Dermatology Annual Meeting, Sarah Coates, MD, FAAD, highlights how social drivers shape pediatric skin health and how clinicians can respond.

Two posters presented at the Society for Pediatric Dermatology's Annual Meeting explore the psychological toll and potential nutritional approaches for managing vitiligo in children and adolescents.

Cory Simpson, MD, PhD, assistant professor of dermatology at the University of Washington, spoke to the need for more treatment options in genetic skin conditions and the possibility of drug repurposing.

With obesity rates rising sharply, the American Academy of Pediatrics calls for multimodal strategies to address the crisis in youth.

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

A review highlights the need for better research on pediatric segmental vitiligo treatments, as current options show mixed results, and at SPD 2025, Hira Ghani, DO, emphasized the importance of recognizing often-overlooked skin conditions in children.

A poster at the Society for Pediatric Dermatology Annual Meeting presented an integrated safety analysis showing rare or no serious adverse events linked to topical Janus kinase inhibitor use in children with atopic dermatitis (AD).

The efficacy of ruxolitinib cream in pediatric patients shows that nonsteroidal management of atopic dermatitis is feasible, said Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital.

Culturally informed, patient-centered strategies are needed to address acne and hyperpigmentation in patients with skin of color.

New data highlight efficacy, safety, and time off treatment with as-needed ruxolitinib cream in pediatric atopic dermatitis.

Rebecca Chacko, MD, discussed exciting advancements in breast cancer care and the future role of emerging therapeutic strategies for early recurrence detection, as part of her panelist role at the Detroit Institute for Value-Based Medicine.

The Society for Pediatric Dermatology’s 50th Annual Meeting will highlight advances in pediatric skin, hair, and nail care, with expert-led sessions on cutting-edge research and therapies.

María Díez Campelo, MD, PhD, concludes by highlighting imetelstat’s real-world quality of life benefits for patients with lower-risk myelodysplastic syndromes (MDS) and the need for improved patient-reported outcome tools and caregiver-focused research.

Imetelstat (Rytelo; Geron) significantly improved and sustained health-related quality of life in patients with lower-risk myelodysplastic syndromes (MDS), with benefits linked directly to the drug rather than patient characteristics.

The phase 3 IMerge trial (NCT02598661) evaluated how treatment with imetelstat impacts health-related quality of life in patients with lower-risk myelodysplastic syndromes (MDS), according to María Díez Campelo, MD, PhD.

Carrie Kitko, MD, explains that axatilimab maintains strong response rates in patients with chronic graft-versus-host disease (GVHD) regardless of previous treatment lines and emphasizes the need to explore combination therapies.

The post hoc analysis of the AGAVE-201 trial found that axatilimab demonstrated consistent response rates in patients with chronic graft-vs-host disease (GVHD), regardless of the number or type of prior therapies.